BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison has maintained a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $32 to $40.
May 10, 2024 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Julian Harrison reaffirmed a Buy rating on Spyre Therapeutics and raised the price target to $40, indicating a positive outlook on the company's stock.
The increase in price target by a reputable analyst like Julian Harrison from BTIG suggests a strong confidence in Spyre Therapeutics' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100